Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Nippon Chemiphar Discontinues Development of NC-2300
August 8, 2011
- Eve No. 1 OTC Analgesic/Antipyretic Drug 3 Months in a Row
August 8, 2011
- R-Tech Ueno Discontinues PI Study of Hypotrichosis Drug in UK
August 8, 2011
- Marketing Expenses Up 1.5% to US$91 Bil. in 2010: CSD Survey
August 8, 2011
- Taiho's TAS-102 Prolongs OS in mCRC: JSMO Annual Meeting
August 8, 2011
- Oncology Products to Contribute to Astellas' Business from 2018 Onward: President Hatanaka
August 8, 2011
- Avastin's Efficacy in Combination with FOLFIRI for Colon Cancer Confirmed in Domestic PII Study
August 8, 2011
- Shionogi to Enter Chinese Market by Acquiring Local Company
August 8, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
- RaQualia Licenses 5-HT4 Partial Agonist to CJ CheilJedang in South Korea
August 8, 2011
- Fujifilm, DRL Announce Plans to Establish Generic Drugs JV in Japan
August 8, 2011
- Astellas Transfers Investigational Anti-arrhythmic Agent to Merck Subsidiary
August 8, 2011
- Revision Proposed to 70% Rule for Pricing of New Generics
August 8, 2011
- Teijin Pharma's Gout Agent Febuxostat Launched in South Korea
August 8, 2011
- Shionogi to Acquire 9 Products from Victory Pharma of the US
August 1, 2011
- FDA's Advisory Committee Does Not Recommend Approval of Dapagliflozin
August 1, 2011
- Korosho, PMDA Providing Risk Info on Drugs Under Review on Websites
August 1, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…